Sarepta Therapeutics reported $94.02M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
Biogen USD 432M 18.9M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Capricor Therapeutics 2.72M 2.09M Sep/2025
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Esperion Therapeutics USD 77.51M 2.81M Sep/2025
Gilead Sciences USD 808M 226M Sep/2025
Incyte USD 1.63B 1.46B Dec/2025
Insmed USD 79.91M 316K Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Moderna USD 317M 50M Dec/2025
Nektar Therapeutics USD 15.56M 1.28M Sep/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Novavax USD 15.23M 35.37M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.93B 927M Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Tectonic Therapeutic USD 1.48M 1.32M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025